New treatments urgently needed, says bone cancer trust

The Bone Cancer Research Trust (BCRT) is calling for new treatments for bone cancers affecting children and young people including osteosarcoma and Ewing's sarcoma,...

Initial EU approval for Onglyza

Onglyza (saxagliptin) has received a CHMP positive opinion as add-on therapy to improve glycaemic control in adult patients with type 2 diabetes. The...

Roche ‘walks away’ from ABPI

Roche has decided not to review its membership of the ABPI in a controversial move that has led analysts to question the effectiveness of...

J&J and Elan form Alzheimer’s agreement

Johnson & Johnson is to acquire the Elan Corporation’s Alzheimer's Immunotherapy Program (AIP Program), through a newly-formed company. As part of the...

HRA Pharma establishes UK presence

HRA Pharma has established a UK subsidiary, HRA Pharma UK Ltd, based in London. This is the company’s second subsidiary in Europe as...

First pediatric PAH therapy approved in EU

Actelion’s pediatric dispersible formulation of Tracleer (bosentan) for the treatment of pulmonary arterial hypertension (PAH) has been approved in the EU. The approval...

Pfizer triumphs at environmental awards

Pfizer has been recognised as a leader in environmental excellence at the recent Business Commitment to the Environment (BCE) awards. Twelve companies received recognition...

CORRECTION: MabThera recommended in Scotland

Scottish physicians are now able to prescribe MabThera (rituximab) on the NHS, following a positive recommendation by the Scottish Medicines Consortium (SMC). MabThera was...

GPs need swine flu guidance

A poll of GPs by has revealed that, so far, only 9% of GPs in the UK have been given regular, clear and concise...

Tamiflu discount for poorer countries

Roche is to provide its antiviral Tamiflu at a lower price to developing countries as part of a new initiative. Under the Tamiflu Reserves...

Latest articles

Maxwellia makes two new appointments

Maxwellia expand their team with two new appointments

Maxwellia has expanded their team of switch experts with two new appointments following their relocation to the Alderley Park Accelerator. 
BMS & Boston Medical Center enter collaboration

BMS & Boston Medical Center announce research collaboration

BMS & Boston Medical Center enter research collaboration to investigate markers of immuno-oncology response and resistance Bristol-Myers Squibb Company...
Syringe with liquid

EC approves KEYTRUDA® as adjuvant therapy

MSD (Merck in the U.S. and Canada) has announced that the European Commission has approved its anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for the adjuvant treatment...